Hundreds of thousands of people with type 2 diabetes in the UK may soon trade their daily insulin injections for a once-weekly jab, slashing the annual number of injections by a staggering 86%. The new treatment, which has received initial approval from the National Institute for Health and Care Excellence (Nice), is said to work as well as daily insulin but requires only a single injection per week.

Diabetes UK has welcomed the move, noting it could be a game-changer for those who struggle with daily injections, including frail individuals, people with sight loss, limited hand movement, or learning disabilities. Douglas Twenefour, head of clinical at Diabetes UK, said the weekly option could help manage diabetes more easily, improving quality of life for many.

Around 4.7 million people in the UK were living with diabetes in 2024-25, with roughly 90% having type 2. The condition impairs the body's ability to produce or use insulin effectively. About 1 in 4 people with type 2 diabetes currently takes insulin.

Helen Knight, director of medicines evaluation at Nice, said the treatment could make a 'real difference' to patients, especially those relying on carers or healthcare professionals for injections. She emphasized that the recommendation was based on rigorous evidence, balancing patient benefits with NHS funding constraints.

However, before patients can access the treatment on the NHS, it must be licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). Health officials are awaiting the MHRA's ruling to determine if it can be rolled out. Nice guidance applies to the NHS in England, with Wales often following suit, while Northern Ireland and Scotland have separate review processes.

So, for now, the nation waits with bated breath - and a slightly lighter needle count - for the MHRA to give the green light.